Liposome-Encapsulated Doxorubicin Citrate and Carboplatin in Treating Patients With Advanced or Metastatic Recurrent Endometrial Cancer

DISEASE CHARACTERISTICS:

• Diagnosis of endometrial carcinoma, including any of the following cellular types:

  • Mixed Mullerian carcinoma
  • Serous carcinoma
  • Clear cell carcinoma
• Primary advanced (FIGO stage III or stage IV) or metastatic recurrent disease
• Disease not curable by surgery
• Measurable disease, defined as ≥ 1 unidimensionally measurable lesion ≥ 20 mm with x-ray, physical exam, or non-spiral CT scan OR ≥ 10 mm with spiral CT scan or MRI
• No known cerebral metastases

PATIENT CHARACTERISTICS:

• ECOG performance status 0-2
• Life expectancy ≥ 12 weeks
• Platelet count ≥ 100,000/mm^3
• ANC ≥ 1,500/mm^3
• Hemoglobin ≥ 10 g/dL
• Creatinine ≤ 1.25 times upper limit of normal (ULN)
• Bilirubin ≤ 1.25 times ULN
• AST/ALT < 3 times ULN
• Glomerular filtration rate ≥ 50 mL/min
• LVEF ≥ 50% by ECHO
• Fertile patients must use effective contraception
• No myocardial infarction within the past 6 months
• No NYHA class II-IV congestive heart failure
• No third degree or complete heart block unless a pacemaker is in place
• No other malignancy within the past 5 years
• No concomitant medical illness (e.g., uncontrolled infection, uncontrolled angina, or other relevant illness) that makes the prescribed treatments within this study unfeasible
• No known hypersensitivity to study drugs
• No psychological, familial, sociological, or geographical condition potentially hampering compliance with the study protocol and follow-up schedule

PRIOR CONCURRENT THERAPY:

• No prior chemotherapy for disease recurrence

• At least 12 months since prior adjuvant therapy containing anthracyclines with cumulative doses not exceeding the following:

  • Epirubicin 600 mg/m²
  • Doxorubicin 300 mg/m²
• At least 6 months since prior adjuvant therapy containing platinum
• At least 4 weeks since completion of radiotherapy involving the whole pelvis
• No concurrent radiotherapy or planned radiotherapy after study
• No concurrent endocrine, immunological, or other anticancer therapy
• No concurrent participation in another investigational drug study